<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02723955</url>
  </required_header>
  <id_info>
    <org_study_id>204691</org_study_id>
    <secondary_id>2016-000148-32</secondary_id>
    <nct_id>NCT02723955</nct_id>
  </id_info>
  <brief_title>Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)</brief_title>
  <official_title>A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody
      intended for the treatment of cancers of different histology. This is a first-time-in-human
      (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and
      preliminary antitumor activity in participants with selected, advanced or recurrent solid
      tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as
      monotherapy and in combination with pembrolizumab, chemotherapy or other immune therapies.
      The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609
      monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part
      2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 or dostarlimab or
      dostarlimab plus cobolimab or Bintrafusp alfa combination dose escalation phase and Part 2B
      expansion phase with pembrolizumab. Part 2A GSK3359609 combinations with chemotherapy will
      only consist of safety run-in cohorts. Each part and phase of the study includes a screening
      period, a treatment period, and a follow-up period. The primary objective of the study is to
      determine the safety, tolerability, maximum tolerated dose or the maximum administered dose
      of GSK3359609 alone or in combination.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of participants with any adverse event(s) (AE)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with serious adverse event(s) (SAE)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or associated with liver injury and impaired liver function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with dose limiting toxicity (DLT)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 4.0, and is considered by the investigator to be clinically relevant and attributed (probably, or possibly) to the study treatment during the first 28 days after the first dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in systolic and diastolic blood pressure (Millimeter of mercury)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Systolic and diastolic blood pressure (Millimeter of mercury) will be measured in semi-supine position after 5 minutes of rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in pulse rate (Beats per minute)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Pulse rate (Beats per minute) will be measured in semi-supine position after 5 minutes of rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in body temperature (Degrees Celsius)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Body temperature (Degrees Celsius) will be measured in semi-supine position after 5 minutes of rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in hemoglobin (Grams per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in hemoglobin (Grams per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in hematocrit (Proportion of red blood cells in blood)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in hematocrit (Proportion of red blood cells in blood) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in red blood cell (RBC) count (Trillion cells per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in RBC (Trillion cells per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in platelet count (Giga cells per Liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in platelet count (Giga cells per Liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in white blood cell (WBC) count (Giga cells per Liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in WBC count (Giga cells per Liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in total neutrophils, eosinophils, monocytes, basophils and lymphocytes (Giga cells per Liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in total neutrophils, eosinophils, monocytes, basophils, and lymphocytes (Giga cells per Liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in blood urea nitrogen (BUN) (Millimoles per Liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in BUN (Millimoles per Liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in creatinine and bilirubin (Micromoles per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in creatinine and bilirubin (Micromoles per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in glucose, calcium, sodium and potassium (Millimoles per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in glucose, calcium, sodium and potassium (Millimoles per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in total protein and albumin (Grams per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in total protein and albumin (Grams per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) (International units per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in AST, ALT and ALP (International units per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with any abnormal findings in urine analysis parameters</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The following urinalysis parameters will be measured: potential of hydrogen (pH), glucose, protein, blood, ketones by dipstick and specific gravity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in Troponin I or Troponin T (nanograms per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Troponin I or Troponin T will be assessed by echocardiogram or multigated acquisition scans (MUGA) (nanograms per liter).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in thyroid stimulating hormone (TSH) (milliunits per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in TSH (milliunits per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Change from Baseline in triiodothyronine (T3) and thyroxine (T4) (nanograms per deciliter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in T3 and T4 (nanograms per deciliter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants requiring dose modifications</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>All dose modifications due to any reason(s) will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of participants with any AEs</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of participants with serious adverse event(s) (SAE)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant or associated with liver injury and impaired liver function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of participants with DLT</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to NCI CTCAE version 4.0, and is considered by the investigator to be clinically relevant and attributed (probably, or possibly) to the study treatment during the first 28 days after the first dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in systolic and diastolic blood pressure (Millimeter of mercury)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Systolic and diastolic blood pressure (Millimeter of mercury) will be measured in semi-supine position after 5 minutes of rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in pulse rate (Beats per minute)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Pulse rate (beats per minute) will be measured in semi-supine position after 5 minutes of rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in body temperature (Degrees Celsius)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Body temperature (Degrees Celsius) will be measured in semi-supine position after 5 minutes of rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in hemoglobin (Grams per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in haemoglobin (Grams per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in hematocrit (Proportion of red blood cells in blood)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in hematocrit (Proportion of red blood cells in blood) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in RBC count (Trillion cells per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in RBC (Trillion cells per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in platelet count (Giga cells per Liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in platelet (Giga cells per Liter) count will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in WBC count (Giga cells per Liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in WBC (Giga cells per Liter) count will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in total neutrophils, eosinophils, monocytes, basophils, and lymphocytes (Giga cells per Liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in total neutrophils, eosinophils, monocytes, basophils, and lymphocytes (Giga cells per Liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in BUN (Millimoles per Liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in BUN (Millimoles per Liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in creatinine and bilirubin (Micromoles per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in creatinine and bilirubin (Micromoles per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in glucose, calcium, sodium and potassium (Millimoles per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in glucose, calcium, sodium and potassium (Millimoles per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in total protein and albumin (Grams per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in total protein and albumin (Grams per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in AST, ALT and ALP (International units per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in AST, ALT and ALP (International units per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of participants with any abnormal findings in urine analysis parameters</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The following urinalysis parameters will be measured: pH, glucose, protein, blood, ketones by dipstick and specific gravity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in Troponin I or Troponin T (nanograms per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Troponin I or Troponin T will be assessed by echocardiogram or MUGA (nanograms per liter).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in TSH (milliunits per liter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in TSH (milliunits per liter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in T3 and T4 (nanograms per deciliter)</measure>
    <time_frame>Baseline and up to 24 months</time_frame>
    <description>Blood samples will be collected at indicated time points and change from Baseline in T3 and T4 (nanograms per deciliter) will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of participants requiring dose modifications</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>All dose modifications due to any reason(s) will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Disease control rate (DCR)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>DCR is defined as the percentage of participants with a confirmed complete response (CR) + partial response (PR) at any time, plus stable disease (SD) &gt;=18 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Overall survival (OS)</measure>
    <time_frame>up to 4 years</time_frame>
    <description>OS is defined as time from the date of first dose of study treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Progression-free survival (PFS)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>PFS is defined as time from the date of first dose of study treatment to the date of disease progression according to clinical or radiographic assessment or death due to any cause, whichever occurs earliest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time to overall response (TTR)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>TTR will be summarized for participants with a confirmed CR or PR and is defined as the time from date of first dose of study treatment to date of first documented confirmed CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Duration of response (DOR)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>DOR will be summarized for participants with a confirmed CR or PR and is defined as the time from date of initial confirmed response to the date of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Overall response rate (ORR)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>ORR is defined as the percentage of participants with a best overall confirmed CR or a PR at any time as per disease-specific criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum observed plasma concentration (Cmax) of GSK3359609</measure>
    <time_frame>Day1:predose,end of infusion(EOI),EOI+30 minutes,+1,+2,+4hours, Day2:EOI+24hours, Day 8 and 15,Day22:pre EOI+4hours,Days29and 36,Days43 to 106:pre EOI+4hours,Day127:pre dose;Week21 then every12weeks postdose(Up to 27months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Minimum observed plasma concentration (Cmin) of GSK3359609</measure>
    <time_frame>Day1:predose,end of infusion(EOI),EOI+30 minutes,+1,+2,+4hours, Day2:EOI+24hours, Day 8 and 15,Day22:pre EOI+4hours,Days29and 36,Days43 to 106:pre EOI+4hours,Day127:pre dose;Week21 then every12weeks postdose(Up to 27months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under the concentration-time curve over the dosing interval (AUC[0-tau]) of GSK3359609 in plasma</measure>
    <time_frame>Day1:predose,end of infusion(EOI),EOI+30 minutes,+1,+2,+4hours, Day2:EOI+24hours, Day 8 and 15,Day22:pre EOI+4hours,Days29and 36,Days43 to 106:pre EOI+4hours,Day127:pre dose;Week21 then every12weeks postdose(Up to 27months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of participants with positive results in Anti-drug antibody (ADA) test by GSK3359609 dose level</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>Blood samples will be collected up to 27 months for ADA test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of participants with positive results in GSK3359609</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>Blood samples will be collected up to 27 months for immunogenicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of participants with DLT following administration of GSK3359609 combination with chemotherapies</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to NCI CTCAE G version 4.0, and is considered by the investigator to be clinically relevant and attributed (probably, or possibly) to the study treatment during the first 28 days after the first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Disease control rate (DCR)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD &gt;=18 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Overall survival (OS)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>OS is defined as time from the date of first dose of study treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Progression-free survival (PFS)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>PFS is defined as time from the date of first dose of study treatment to the date of disease progression according to clinical or radiographic assessment or death due to any cause, whichever occurs earliest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Time to overall response (TTR)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>TTR will be summarized for participants with a confirmed CR or PR and is defined as the time from date of first dose of study treatment to date of first documented confirmed CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Duration of response (DOR)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>DOR will be summarized for participants with a confirmed CR or PR and is defined as the time from date of initial confirmed response to the date of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Overall response rate (ORR)</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>ORR is defined as the percentage of participants with a best overall confirmed CR or a PR at any time as per disease-specific criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of GSK3359609 (Q3W dosing)</measure>
    <time_frame>Day1:predose,EOI,EOI+30 minutes,+1,+2,+4hours, Day2:EOI+24hours, Day 8 and 15, Day22:pre EOI+4hours,Days29 and 36,Days43 to 106:pre EOI+4hours,Day127:pre dose;Week21 then every 12weeks postdose (Up to 27months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of GSK3359609 (Q3W dosing)</measure>
    <time_frame>Day1:predose,EOI,EOI+30 minutes,+1,+2,+4hours, Day2:EOI+24hours, Day 8 and 15, Day22:pre EOI+4hours,Days29 and 36,Days43 to 106:pre EOI+4hours,Day127:pre dose;Week21 then every 12weeks postdose (Up to 27months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC(0-tau) of GSK3359609 (Q3W dosing)</measure>
    <time_frame>Day1:predose,EOI,EOI+30 minutes,+1,+2,+4hours, Day2:EOI+24hours, Day 8 and 15, Day22:pre EOI+4hours,Days29 and 36,Days43 to 106:pre EOI+4hours,Day127:pre dose;Week21 then every 12weeks postdose (Up to 27months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of GSK3174998</measure>
    <time_frame>Day 1: predose, EOI, EOI+4 hours, EOI+24 hours, Day 8 and 15, Day22: predose, Day 43:predose, EOI,EOI+4hours, Day 64 and 85: predose, EOI+4hours, Day 106: predose,Day127:pre dose;Week21 then every 12weeks postdose (Up to 24months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of GSK3174998</measure>
    <time_frame>Day 1: predose, EOI, EOI+4 hours, EOI+24 hours, Day 8 and 15, Day22: predose, Day 43:predose, EOI,EOI+4hours, Day 64 and 85: predose, EOI+4hours, Day 106: predose,Day127:pre dose;Week21 then every 12weeks postdose (Up to 24months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC(0-tau) of GSK3174998</measure>
    <time_frame>Day 1: predose, EOI, EOI+4 hours, EOI+24 hours, Day 8 and 15, Day22: predose, Day 43:predose, EOI,EOI+4hours, Day 64 and 85: predose, EOI+4hours, Day 106: predose,Day127:pre dose;Week21 then every 12weeks postdose (Up to 24months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of Pembrolizumab (Q3W dosing)</measure>
    <time_frame>Day 1: pre-dose, EOI + 30 minutes, Day 2: EOI+24 hours, Days 8 and 15, Days 22, 43, 85, and 106: predose, Days 29, 36 and 64, Day 127: predose, and Week 21 then every 12 weeks postdose (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of Pembrolizumab (Q3W dosing)</measure>
    <time_frame>Day 1: pre-dose, EOI + 30 minutes, Day 2: EOI+24 hours, Days 8 and 15, Days 22, 43, 85, and 106: predose, Days 29, 36 and 64, Day 127: predose, and Week 21 then every 12 weeks postdose (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC(0-tau) of Pembrolizumab (Q3W dosing)</measure>
    <time_frame>Day 1: pre-dose, EOI + 30 minutes, Day 2: EOI+24 hours, Days 8 and 15, Days 22, 43, 85, and 106: predose, Days 29, 36 and 64, Day 127: predose, and Week 21 then every 12 weeks postdose (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of participants with positive results in ADA test by GSK3359609 in combination with pembrolizumab or GSK3174998 dose level</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>Blood samples will be collected up to 27 months for ADA test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of participants with positive results in Pembrolizumab</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>Blood samples will be collected up to 27 months for immunogenicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of participants with positive results in GSK3174998</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>Blood samples will be collected up to 27 months for immunogenicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of GSK3359609 combination with chemotherapies</measure>
    <time_frame>Day 1: predose, EOI, EOI+2 hours, EOI+4 hours, Days 22, 64, 106, and 127: EOI, EOI+ 2 hours post chemotherapy (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of GSK3359609 combination with chemotherapies</measure>
    <time_frame>Day 1: predose, EOI, EOI+2 hours, EOI+4 hours, Days 22, 64, 106, and 127: EOI, EOI+ 2 hours post chemotherapy (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of participants with positive results in ADA test by GSK3359609 combination with chemotherapies dose level</measure>
    <time_frame>Up to 27 months</time_frame>
    <description>Blood samples will be collected up to 27 months for ADA test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of GSK3359609 (Q6W dosing)</measure>
    <time_frame>Day1:predose,EOI,EOI+30 minutes,+1,+2,+4hours, Day2:EOI+24hours, Days 8, 15, 22, 29 and 36:pre dose,Days43 and 85:pre EOI+4hours,Days 64,106 and 127:pre dose;Week21 then every12weeks postdose (Up to 27months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of GSK3359609 (Q6W dosing)</measure>
    <time_frame>Day1:predose,EOI,EOI+30 minutes,+1,+2,+4hours, Day2:EOI+24hours, Days 8, 15, 22, 29 and 36:pre dose,Days43 and 85:pre EOI+4hours,Days 64,106 and 127:pre dose;Week21 then every 12weeks postdose (Up to 27months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC(0-tau) of GSK3359609 (Q6W dosing)</measure>
    <time_frame>Day1:predose,EOI,EOI+30 minutes,+1,+2,+4hours, Day2:EOI+24hours, Days 8, 15, 22, 29 and 36:pre dose,Days43 and 85:pre EOI+4hours,Days 64,106 and 127:pre dose;Week21 then every12weeks postdose (Up to 27months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of Pembrolizumab (Q6W dosing)</measure>
    <time_frame>Day 1: pre-dose, EOI + 30 minutes, Day 2: EOI+24 hours, Day 8, 15, 22, 29, 36, 64 and 106, Days 43, 85 and 127: predose, and Week 21 then every 12 weeks postdose (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of Pembrolizumab (Q6W dosing)</measure>
    <time_frame>Day 1: pre-dose, EOI + 30 minutes, Day 2: EOI+24 hours, Day 8, 15, 22, 29, 36, 64 and 106, Days 43, 85 and 127: predose, and Week 21 then every 12 weeks postdose (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC(0-tau) of Pembrolizumab (Q6W dosing)</measure>
    <time_frame>Day 1: pre-dose, EOI + 30 minutes, Day 2: EOI+24 hours, Day 8, 15, 22, 29, 36, 64 and 106, Days 43, 85 and 127: predose, and Week 21 then every 12 weeks postdose (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of dostarlimab</measure>
    <time_frame>Day 1, 22, 85 and 127: pre-dose, EOI, then pre-dose every 18 weeks (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of dostarlimab</measure>
    <time_frame>Day 1, 22, 85 and 127: pre-dose, EOI, then pre-dose every 18 weeks (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC(0-tau) of dostarlimab</measure>
    <time_frame>Day 1, 22, 85 and 127: pre-dose, EOI, then pre-dose every 18 weeks (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of cobolimab</measure>
    <time_frame>Days 1, 22, 43, 64, 85, 106 and 127: pre-dose, EOI + 0.5 hours then pre-dose every 18 weeks (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of cobolimab</measure>
    <time_frame>Days 1, 22, 43, 64, 85, 106 and 127: pre-dose, EOI + 0.5 hours then pre-dose every 18 weeks (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC(0-tau) of cobolimab</measure>
    <time_frame>Days 1, 22, 43, 64, 85, 106 and 127: pre-dose, EOI + 0.5 hours then pre-dose every 18 weeks (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of bintrafusp alfa</measure>
    <time_frame>Day 1: pre-dose, EOI, EOI + 30 minutes, Day 2: EOI+24 hours, Days 8 and 15, Days 22, 43, 64, 85, 106: pre-dose, EOI; Day 127: pre-dose and pre-dose at Week 21 then every 12 weeks (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of bintrafusp alfa</measure>
    <time_frame>Day 1: pre-dose, EOI, EOI + 30 minutes, Day 2: EOI+24 hours, Days 8 and 15, Days 22, 43, 64, 85, 106: pre-dose, EOI; Day 127: pre-dose and pre-dose at Week 21 then every 12 weeks (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of Cmin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC(0-tau) of bintrafusp alfa</measure>
    <time_frame>Day 1: pre-dose, EOI, EOI + 30 minutes, Day 2: EOI+24 hours, Days 8 and 15, Days 22, 43, 64, 85, 106: pre-dose, EOI; Day 127: pre-dose and pre-dose at Week 21 then every 12 weeks (Up to 27 months)</time_frame>
    <description>Blood samples will be collected at the indicated time points for evaluation of AUC(0-tau).</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">873</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part 1A: Dose escalation GSK3359609</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3359609 as an intravenous (IV) infusion administered once every 3 weeks (Q3W) continuously at a dose level dependent on to which dose level the participant is accrued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B: Expansion GSK3359609</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3359609 as an IV infusion administered Q3W continuously at a dose level chosen for further exploration in dose expansion cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with 200 milligram (mg) of pembrolizumab as an IV infusion administered once Q3W continuously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+GSK3174998)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with GSK3174998 as an IV infusion administered once Q3W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: Safety run-in (GSK3359609+chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants participating in Part 2A chemotherapy combination cohorts will receive GSK3359609 in combination with chemotherapy at doses and schedules based on standard of care practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+ dostarlimab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with dostarlimab administered as an IV infusion at 500 mg Q3W for 4 cycles followed by 1000 mg Q6W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+dostarlimab+cobolimab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with dostarlimab administered as an IV infusion at 500 mg Q3W for 4 cycles followed by 1000 mg Q6W plus cobolimab administered as an IV infusion at 300 mg Q3W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+bintrafusp alfa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with bintrafusp alfa administered as an IV infusion at 2400 mg Q3W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2B: Expansion-GSK3359609</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with 200 mg of pembrolizumab as an IV infusion administered once Q3W continuously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2B: Expansion-GSK3359609 (Q6W)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GSK3359609 as an IV infusion administered once every 6 weeks (Q6W) continuously in combination with 400 mg of pembrolizumab as an IV infusion administered Q6W continuously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3359609 IV infusion</intervention_name>
    <description>GSK3359609 diluted product will be administered as an IV infusion to participants Q3W or Q6W.</description>
    <arm_group_label>Part 1A: Dose escalation GSK3359609</arm_group_label>
    <arm_group_label>Part 1B: Expansion GSK3359609</arm_group_label>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+ dostarlimab)</arm_group_label>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+GSK3174998)</arm_group_label>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+bintrafusp alfa)</arm_group_label>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+dostarlimab+cobolimab)</arm_group_label>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+pembrolizumab)</arm_group_label>
    <arm_group_label>Part 2A: Safety run-in (GSK3359609+chemotherapy)</arm_group_label>
    <arm_group_label>Part 2B: Expansion-GSK3359609</arm_group_label>
    <arm_group_label>Part 2B: Expansion-GSK3359609 (Q6W)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3174998 IV infusion</intervention_name>
    <description>GSK3174998 diluted product will be administered as an IV infusion to participants Q3W.</description>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+GSK3174998)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab 200 mg IV infusion</intervention_name>
    <description>Pembrolizumab 200 mg will be administered as an IV infusion to participants Q3W.</description>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+pembrolizumab)</arm_group_label>
    <arm_group_label>Part 2B: Expansion-GSK3359609</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel 75 milligrams per square meters (mg/m^2) IV infusion</intervention_name>
    <description>Docetaxel 75 mg/m^2 diluted product will be administered as an IV infusion to participants Q3W.</description>
    <arm_group_label>Part 2A: Safety run-in (GSK3359609+chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed 500 mg/m^2 plus Carboplatin area under the curve (AUC) 4-6 mg/mL per minute IV infusion</intervention_name>
    <description>Pemetrexed 500 mg/m^2 diluted product in combination with Carboplatin AUC 4-6 milligram per milliliter (mg/mL) per minute (diluted product), will be administered as an IV infusion to participants Q3W.</description>
    <arm_group_label>Part 2A: Safety run-in (GSK3359609+chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel 200 mg/m^2 plus Carboplatin AUC 4-6 mg/mL per minute IV infusion</intervention_name>
    <description>Paclitaxel 200 mg/m^2 diluted product in combination with Carboplatin AUC 4-6 mg/mL per minute (diluted product), will be administered as an IV infusion to participants Q3W.</description>
    <arm_group_label>Part 2A: Safety run-in (GSK3359609+chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine 1250 mg/m^2 plus Carboplatin AUC 4-6 mg/mL per minute IV infusion</intervention_name>
    <description>Gemcitabine 1250 mg/m^2 diluted product in combination with Carboplatin AUC 4-6 mg/mL per minute (diluted product), will be administered as an IV infusion to participants Q3W.</description>
    <arm_group_label>Part 2A: Safety run-in (GSK3359609+chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil (5-FU) 1000 mg/m^2/day plus carboplatin or cisplatin</intervention_name>
    <description>Carboplatin AUC 4-6 mg/mL per minute or cisplatin at 100 mg/m^2 will be combined with 5-FU at 1000 mg/m^2/day will be administered as an IV infusion to participants Q3W.</description>
    <arm_group_label>Part 2A: Safety run-in (GSK3359609+chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab 400 mg IV infusion</intervention_name>
    <description>Pembrolizumab 400 mg will be administered as an IV infusion to participants Q6W.</description>
    <arm_group_label>Part 2B: Expansion-GSK3359609 (Q6W)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dostarlimab</intervention_name>
    <description>Dostarlimab will be administered as an IV infusion at a dose of 500 mg once Q3W for 4 doses followed by a dose of 1000 mg Q6W.</description>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+ dostarlimab)</arm_group_label>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+dostarlimab+cobolimab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobolimab</intervention_name>
    <description>Cobolimab will be administered as an IV infusion at a dose of 300 mg Q3W.</description>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+dostarlimab+cobolimab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bintrafusp alfa</intervention_name>
    <description>Bintrafusp alfa will be administered as an IV infusion at a dose of 2400 mg Q3W.</description>
    <arm_group_label>Part 2A: Dose escalation (GSK3359609+bintrafusp alfa)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Capable of giving signed, written informed consent.

          -  Male or female, age &gt;=18 years (at the time consent is obtained).

          -  Histological or cytological documentation of an invasive malignancy that was diagnosed
             as locally advanced/metastatic or relapsed/refractory and is of one of the following
             tumor types: bladder/urothelial cancer of the upper and lower urinary tract; cervical;
             colorectal (includes appendix); esophagus, squamous cell; head and neck carcinoma;
             melanoma; malignant pleural mesothelioma (MPM); non-small-cell lung cancer (NSCLC),
             prostate; Microsatellite Instability-High/deficient mismatch repair (MSI-H/dMMR) tumor
             (Part 1B and Part 2B) and Human Papilloma Virus (HPV)-positive or Epstein-Barr
             (EBV)-positive tumor (Part 1B and Part 2B).

          -  Disease that has progressed after standard therapy for the specific tumor type, or for
             which standard therapy has proven to be ineffective, intolerable, or is considered
             inappropriate, or if no further standard therapy exists; exceptions are in these tumor
             types in which pembrolizumab single agent may be a standard: NSCLC, head and neck
             squamous cell cancer (HNSCC), bladder/urothelial cancer, MSI-H/dMMR cancers and
             melanoma and cervical cancer. In Part 2B pembrolizumab combination expansion cohorts,
             prior treatment with anti-Programmed cell death protein 1(PD-1)/ Ligand-1 (L1) may not
             be required. 1) Participants must not have received more than 5 prior lines of therapy
             for advanced disease including both standards of care and investigational therapies.
             2) Participants who received prior PD-1/L1 therapy must fulfill the following
             requirements (Part 1B [except PK/PD cohort]/ Part 2B):a) Have achieved a CR, PR or SD
             and subsequently had disease progression while still on PD-1/L1 therapy; b) Have
             received at least 2 doses of an approved PD-1/L1 inhibitor (by any regulatory
             authority), c) Have demonstrated disease progression as defined by Response Evaluation
             Criteria in Solid Tumors (RECIST) version 1.1 within 18 weeks from the last dose of
             the PD-1/L1 inhibitor. The initial evidence of disease progression is to be confirmed
             by a second assessment no less than four weeks from the date of the first documented
             Progressive Disease (PD) (the confirmatory scan could be the Baseline eligibility scan
             for this study). 3) In Part 2A 5-fluorouracil (FU)/platinum combination with
             GSK3359609 and pembrolizumab cohort, participants must not have received prior
             systemic therapy administered in the recurrent or metastatic setting (with the
             exception of systemic therapy given as part of multimodal treatment for locally
             advanced disease).

          -  Archival tumor tissue obtained at any time from the initial diagnosis to study entry;
             a fresh tumor biopsy using a procedure that is safe for the participant on a lesion
             not previously irradiated unless lesion progressed will be required if archival tissue
             is unavailable.

          -  Agree to undergo a pre-treatment and on treatment biopsy and have disease amenable to
             biopsy required in pharmacokinetic (PK) / pharmacodynamics (PD), dose randomized
             HNSCC, Melanoma dose expansion and Biomarker cohorts..

          -  Measurable disease per RECIST version 1.1. Palpable lesions that are not measurable by
             radiographic or photographic evaluations may not be utilized as the only measurable
             lesion. Any measurable lesion biopsied at Screening cannot be followed as a
             target/index lesion unless agreed upon by GlaxoSmithKline (GSK).

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

          -  Life expectancy of at least 12 weeks.

          -  Adequate organ function.

          -  QT interval corrected for heart rate according to Fridericia's formula (QTcF) &lt;450
             milliseconds (msec) or QTcF &lt;480 msec for participants with bundle branch block.

          -  A female participant is eligible to participate if she is not pregnant (as confirmed
             by a negative serum beta-human chorionic gonadotrophin [beta-hCG] test in females of
             reproductive potential), and not lactating or reproductive potential agrees to follow
             one of the options listed in protocol from 30 days prior to the first dose of study
             medication and until 120 days after the last dose of study treatment.

          -  Male participants with female partners of child bearing potential must agree to use
             one of the methods of contraception specified in protocol from time of first dose of
             study treatment until 120 days after the last dose of study treatment.

          -  Documented HPV/ EBV-positive tumor as determined by a local laboratory for Part 1B and
             Part 2B pembrolizumab combination viral-positive expansion cohorts only.

          -  Documented MSI-H or dMMR-positive tumor as determined by local laboratory for Part 1B
             and Part 2B pembrolizumab combination MSI-H/dMMR expansion cohorts only.

          -  Documented ICOS expression using an analytically validated immunohistochemistry (IHC)
             assay by central laboratory for Part 1B biomarker cohort only.

          -  Documented gene expression (GEX) result using an analytically validated method by
             central laboratory (Part 1B Biomarker Cohort only).

          -  PD-L1 combined positive score (CPS) &lt;1 using the Food and Drug Administration (FDA)
             approved PD-L1 IHC 22C3 pharmdx assay by central laboratory testing for Part 2B HNSCC
             PD-L1 CPS &lt;1 Cohort. Documented test result from FDA approved PD-L1 IHC 22C3 pharmDx
             assay in local laboratory, if available, may be accepted in lieu of the central
             laboratory test result.

          -  Defined PD-L1 expression using the Ventana PD-L1 (SP263) IHC assay by central testing
             for enrollment in the PK/PD cohort with bintrafusp alfa, dostarlimab, dostarlimab and
             cobolimab combination studies (Part 2A).

        Exclusion Criteria

          -  Prior treatment with the following therapies:

               -  Anticancer therapy within 30 days or 5 half-lives of the drug, whichever is
                  shorter. At least 14 days must have elapsed between the last dose of prior
                  anticancer agent and the first dose of study drug is administered.

               -  Part 2B (GSK3359609/pembrolizumab combination): prior pembrolizumab washout is
                  not required.

               -  Prior radiation therapy: permissible if at least one non-irradiated measurable
                  lesion is available for assessment according to RECIST version 1.1 or if a
                  solitary measurable lesion was irradiated, objective progression is documented. A
                  wash out of at least two weeks before start of study drug for radiation of any
                  intended use to the extremities for bone metastases and 4 weeks for radiation to
                  the chest, brain, or visceral organs is required.  Investigational therapy
                  within 30 days or 5 half-lives of the investigational product (whichever is
                  shorter). At least 14 days must have elapsed between the last dose of
                  investigational agent and the first dose of study drug is administered.

          -  Prior allogeneic or autologous bone marrow transplantation or other solid organ
             transplantation.

          -  Toxicity from previous anticancer treatment

          -  Invasive malignancy or history of invasive malignancy other than disease under study
             within the last two years except: Any other invasive malignancy for which the
             participant was definitively treated, has been disease-free for &lt;=2 years and in the
             opinion of the principal investigator and GSK Medical Monitor will not affect the
             evaluation of the effects of the study treatment on the currently targeted malignancy,
             may be included in this clinical trial; and curatively treated non-melanoma skin
             cancer.

          -  Central nervous system (CNS) metastases, with the following exception:  Participants
             who have previously-treated CNS metastases, are asymptomatic, and have no requirement
             for steroids at least 14 days prior to first dose of study drug. Participants with
             carcinomatous meningitis or leptomeningeal spread are excluded regardless of clinical
             stability.

          -  Received transfusion of blood products (including platelets or red blood cells) or
             administration of colony stimulating factors (including granulocyte colony-stimulating
             factor [G-CSF], granulocyte-macrophage colony-stimulating factor, recombinant
             erythropoietin) within 14 days prior to the first dose of GSK3359609.

          -  Major surgery &lt;=4 weeks before the first dose of study treatment. Participants must
             have also fully recovered from any surgery (major or minor) and/or its complications
             before initiating study treatment.

          -  Active autoimmune disease that has required systemic treatment within the last two
             years (i.e., with use of disease modifying agents, corticosteroids or
             immunosuppressive drugs). Replacement therapy (e.g., thyroxine or physiologic
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is
             not considered a form of systemic treatment.

          -  Concurrent medical condition requiring the use of systemic immunosuppressive
             medications within 7 days before the first dose of study treatment. Physiologic doses
             of corticosteroids for treatment of endocrinopathies or steroids with minimal systemic
             absorption, including topical, inhaled, or intranasal corticosteroids may be continued
             if the participant is on a stable dose.

          -  Condition requiring treatment with strong inhibitors/inducers of cytochrome (CYP) p450
             3A4 within 7 days prior to first dose of chemotherapy (requirement applies to
             participants enrolled to Part 2 chemotherapy combination with docetaxel).

          -  Active infection requiring systemic therapy, known human immunodeficiency virus
             infection, or positive test for hepatitis B active infection or hepatitis C active
             infection.

          -  Current active liver or biliary disease (with the exception of Gilbert's syndrome or
             asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease
             per investigator assessment).

          -  Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel
             disease, intra-abdominal abscess, or gastrointestinal obstruction that required
             surgery.

          -  Receipt of any live vaccine within 4 weeks prior to first dose of study treatment.

          -  Recent history of allergen desensitization therapy within 4 weeks of starting study
             treatment.

          -  History of severe hypersensitivity to monoclonal antibodies or to the chemotherapies
             under investigation including any ingredient used in the formulation.

          -  History or evidence of cardiac abnormalities.

          -  History of (current and past) idiopathic pulmonary fibrosis, pneumonitis (for past
             pneumonitis exclusion only if steroids were required for treatment), interstitial lung
             disease, or organizing pneumonia. Note: post-radiation changes in the lung related to
             prior radiotherapy and/or asymptomatic radiation-induced pneumonitis not requiring
             treatment may be permitted if agreed by the investigator and Medical Monitor.

          -  Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural
             effusions.

          -  Any serious and/or unstable pre-existing medical, psychiatric disorder, or other
             condition that could interfere with the participant's safety, obtaining informed
             consent, or compliance to the study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Erminia Massarelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ani Balmanoukian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Judy S Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Naiyer Rizvi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Raid Aljumaily</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony J Olszanski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Todd M Bauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Leora Horn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hui Gan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Danny Rischin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Millward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aaron Hansen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Antoine Italiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lyon cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Catherine Terret</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christophe Le Tourneau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villejuif cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Angevin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michele Maio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yasutoshi Kuboki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Masayuki Takeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Noboru Yamamoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Frans L. Opdam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Elena Garralda Cabanas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ana Arance Fernndez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Victor Moreno Garca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mlaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Manuel Trigo Prez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Vicente Baz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICOS receptor agonist antibody</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>KEYNOTE-478</keyword>
  <keyword>GSK3359609</keyword>
  <keyword>Cohort expansion</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>Dostarlimab</keyword>
  <keyword>Cobolimab</keyword>
  <keyword>Bintrafusp alfa</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

